Tag Archives: HEA

ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial

PALO ALTO, California, April 11, 2015 /PRNewswire/ — ReCor Medical, Inc., a Palo Alto– and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka…

China Jo-Jo Drugstores Announces Change in Auditing Firm

HANGZHOU, China, April 10, 2015 /PRNewswire/ — China Jo-Jo Drugstores, Inc. ("China Jo-Jo", or the "Company") (NASDAQ CM: CJJD), a leading China-based retail and wholesale distributor of pharmaceutical and health…

BNC105 Biomarker Data to Be Presented at Asian Oncology Conference

ADELAIDE, Australia, April 10, 2015 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105…

Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results

BEIJING, April 10, 2015 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for…

IBA and Toshiba Sign Strategic Partnership in Particle Therapy

LOUVAIN-LA-NEUVE, Belgium and TOKYO, April 9, 2015 /PRNewswire/ — Collaboration signed to enhance access to proton therapy and carbon therapy worldwide  Toshiba Medical Systems Corporation to become IBA’s Proteus®ONE distributor in Japan  IBA to become…

Directors from Chinese and American Hospitals Meet to Discuss Big Data Applications at Harvard Medical School

Market Value of China’s Independent Medical Laboratory Market on Track to Reach CNY32 Billion BOSTON, April 9, 2015 /PRNewswire/ — At this year’s recently held National People’s Congress and Chinese…

VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

Strategic investment to accelerate development of NuQ? colorectal cancer detection test NAMUR, Belgium, April 9, 2015 /PRNewswire/ — VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing…

Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma

– Anisina kills melanoma cells regardless of their mutation status – Melanoma cells with normal and mutated BRAF gene killed by Anisina – Anisina to come into the clinic as…